ARCA biopharma, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>ARCA biopharma, Inc. has filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing financial information and significant corporate events.</b>

AI Summary

ARCA biopharma, Inc. (ORKA) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. ARCA biopharma, Inc. filed a 10-Q report for the period ending March 31, 2024. The filing includes data related to various financial statement line items and dates. Key dates mentioned include March 31, 2024, December 31, 2023, and April 3, 2024. The company was formerly known as NUVELO INC and HYSEQ INC. The filing references a Merger Agreement and Subsequent Events related to Arca Biopharma Inc. and Oruka Therapeutics Inc. on April 3, 2024.

Why It Matters

For investors and stakeholders tracking ARCA biopharma, Inc., this filing contains several important signals. This 10-Q filing provides investors and analysts with the latest financial performance and operational updates for ARCA biopharma, Inc. as of Q1 2024. The inclusion of subsequent events, such as the merger agreement with Oruka Therapeutics Inc., offers insight into potential future strategic directions and value creation opportunities.

Risk Assessment

Risk Level: — ARCA biopharma, Inc. shows moderate risk based on this filing. The filing is a standard 10-Q report with no immediate red flags, indicating routine financial disclosure.

Analyst Insight

Monitor future filings for details on the merger agreement with Oruka Therapeutics Inc. and its financial implications.

Key Numbers

• 2024-03-31 — Reporting Period End Date (Conformed Period of Report)
• 2024-04-25 — Filing Date (Filed as of Date)
• 2024-04-03 — Subsequent Event Date (Merger Agreement and Subsequent Event)

Key Players & Entities

• ARCA biopharma, Inc. (company) — Filer name
• NUVELO INC (company) — Former company name
• HYSEQ INC (company) — Former company name
• Oruka Therapeutics Inc. (company) — Mentioned in relation to a merger agreement and subsequent event

FAQ

Industry Context

ARCA biopharma operates within the biopharmaceutical industry, focusing on the development of therapeutic products.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including quarterly reporting requirements under the Securities Exchange Act of 1934.

What Investors Should Do

1. Analyze the financial statements within the 10-Q for key performance indicators.
2. Investigate the details and implications of the merger agreement with Oruka Therapeutics Inc.
3. Track any further disclosures or updates regarding the company's product development pipeline.

Key Dates

• 2024-03-31: Quarterly Period End — Financial reporting period for the 10-Q
• 2024-04-25: Filing Date — Date the 10-Q was officially filed with the SEC
• 2024-04-03: Subsequent Event — Date of Merger Agreement and related events

Year-Over-Year Comparison

This filing represents the first 10-Q for the fiscal year 2024, providing updated financial and operational information compared to the previous fiscal year's filings.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ABIO Nasdaq Capital Marke

Filing Documents

• abio-20240331.htm (10-Q) — 1169KB
• abio-ex31_1.htm (EX-31.1) — 11KB
• abio-ex31_2.htm (EX-31.2) — 11KB
• abio-ex32_1.htm (EX-32.1) — 13KB
• 0000950170-24-048329.txt (&nbsp;) — 4090KB
• abio-20240331.xsd (EX-101.SCH) — 699KB
• abio-20240331_htm.xml (XML) — 429KB

Financial Information

Part I Financial Information

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 3

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 17

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 24

Controls and Procedures

Item 4. Controls and Procedures 24

Other Information

Part II Other Information

Legal Proceedings

Item 1. Legal Proceedings 25

Risk Factors

Item 1A. Risk Factors 25

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 54

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 54

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 54

Other Information

Item 5. Other Information 54

Exhibits

Item 6. Exhibits 55 Signature 57 2

FIN ANCIAL INFORMATION

PART I. FIN ANCIAL INFORMATION I TEM 1. FINANCIAL STATEMENTS ARCA BIOPHARMA, INC. BALANCE SHEETS (Unaudited) March 31, December 31, 2024 2023 (in thousands, except share and per share amounts) ASSETS Current assets: Cash and cash equivalents $ 35,903 $ 37,431 Other current assets 767 161 Total current assets 36,670 37,592 Right-of-use asset - operating 17 247 Property and equipment, net 7 10 Other assets 12 12 Total assets $ 36,706 $ 37,861 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 529 $ 362 Accrued compensation and employee benefits 84 100 Accrued expenses and other liabilities 968 175 Total current liabilities 1,581 637 Operating lease liability, net of current portion — 204 Total liabilities 1,581 841 Commitments and contingencies Stockholders' equity: Common stock, $ 0.001 par value; 100 million shares authorized at March 31, 2024 and December 31, 2023; 14,501,143 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively 14 14 Additional paid-in capital 225,861 225,747 Accumulated deficit ( 190,750 ) ( 188,741 ) Total stockholders' equity 35,125 37,020 Total liabilities and stockholders' equity $ 36,706 $ 37,861 See accompanying Notes to Financial Statements 3 ARCA BIOPHARMA, INC. (unaudited) March 31, 2024 2023 (in thousands, except share and per share amounts) Costs and expenses: General and administrative $ 2,317 $ 1,406 Research and development (related party - $ 0 and $ 108 as of March 31, 2024 and 2023, respectively) 165 390 Total costs and expenses 2,482 1,796 Loss from operations ( 2,482 ) ( 1,796 ) Interest and other income 473 450 Net loss $ ( 2,009 ) $ ( 1,346 ) Net loss per share: Basic and diluted $ ( 0.14 ) $ ( 0.09 )

NOTES TO FINANCIAL STATEMENTS

NOTES TO FINANCIAL STATEMENTS (unaudited) (1) The Company and Summary of Significant Accounting Policies Description of Business ARCA biopharma, Inc. (the Company or ARCA), a Delaware corporation, is headquartered in Westminster, Colorado. The Company is dedicated to applying a precision medicine approach to the development and commercialization of genetically targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). In April 2022, ARCA established a Special Committee of the board of directors (the "Board") of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic review process, the Company explored potential strategic alternatives that included, without limitation, an acquisition, merger, business combination or other transactions. The Company has and is continuing to explore strategic alternatives related to its product candidates and related assets, including, without limitation, licensing transactions and asset sales. On April 3, 2024, following a comprehensive review of strategic alternatives, the Company, Atlas Merger Sub Corp., a Delaware corporation and a wholly-owned subsidiary of ARCA ("Merger Sub I"), Atlas Merger Sub II LLC, a Delaware limited liability company and a wholly-owned subsidiary of ARCA ("Merger Sub II") and Oruka Therapeutics, Inc., a Delaware corporation ("Oruka " ), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub I will merge with and into Oruka, with Oruka continuing as a wholly owned subsidiary of ARCA and the surviving corporation of the merger (the "First Merger") and as part of the same overall transaction, the surviving corporation in the First Mer

View Full Filing

View this 10-Q filing on SEC EDGAR